Streetwise Reports' Article Archives — September 2018 back to current month (14)

Life Sciences Company Hits Sales Milestone with Livestock Product (09/29/2018)

With this development, the Canadian firm entered a new geography and an additional market segment.


Partnership Greenlighted for Canadian Biotech and Chinese Health Products Firm (09/26/2018)

This regenerative medicine company moves one step closer to commercialization of its cell therapies in East Asia.


NIH Selects Biopharma's Lead Asset for Commercialization Accelerator Program (09/26/2018)

A Maxim Group analyst reported on news and upcoming catalysts for this late-stage drug developer.


Biotech's Preliminary Immunotherapy Data 'Positive,' Earns Coverage in Medical Journal (09/26/2018)

An H.C. Wainwright & Co. report reviewed both the results and an "unusual" highlight from this firm's trial in head-and-neck cancer.


Life Science Company Sells Large Order of Non-Antibiotic Growth Promoter for Livestock (09/25/2018)

This is the second large shipment to the Philippine distributor.


This Company Has Better Numbers than Tilray at 1/25th the Price (09/24/2018)

Tilray's wild fluctuations have grabbed the headlines the past few days, but Fincom Investment Partners profiles a rapidly emerging player in the cannabis realm that the firm believes has much more to offer.


Coverage Initiated on 'Emerging Antibiotics Growth Story with Multiple Levers for Upside' (09/19/2018)

An H.C. Wainwright & Co. report outlined the investment thesis for this U.S.-based biopharmaceutical firm.


Cancer Vaccine Developer Expands Its Collaboration with Merck (09/19/2018)

A Mackie Research Capital report tells how this biotech will benefit from its new and existing programs with this specific partner.


U.S. Biotech Partner Obtains Marketing Authorization for ADHD Treatment in Taiwan (09/18/2018)

Permission has been obtained to distribute time-release capsules.


Why Tiny ITUS's CAR-T Therapy Could Be a Big Deal in Cancer Treatment (09/14/2018)

With CAR-T being the hottest space in cancer therapy, Daniel Carlson of Tailwinds Research profiles an innovative company that has been collaborating with a major cancer center.


Canadian Biopharma to Outlicense Pain Drug to South Korean Firm (09/12/2018)

An Echelon Wealth Partners report discussed the deal terms.


Biopharma's Positive FDA Meeting Outlines Path Forward for Trial (09/11/2018)

A ROTH Capital Partners note explained the outcome of the tĂȘte-a-tĂȘte and its implications.


Coverage Initiated on Firm with Paradigm-Shifting Colonoscopy Device (09/05/2018)

A Ladenburg Thalmann report covered the asset, product market and financial projections of this Florida-based company.


Final Approval of Biopharma's Lead Candidate Both Likely and Imminent (09/05/2018)

A ROTH Capital Partners report provided the takeaways from a recent meeting with the management team for this company, which is targeting an orphan indication.


More Archives

2024May Apr Mar Feb Jan

2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Notable Quotes